

4-(Pyridin-2-yl)thiazol-2-yl thioglycosides as bidentate ligands for oligosaccharide synthesis *via* temporary deactivation†

Papapida Pornsuriyasak, Nigam P. Rath and Alexei V. Demchenko*

Received (in College Park, MD, USA) 23rd June 2008, Accepted 28th August 2008

First published as an Advance Article on the web 1st October 2008


DOI: 10.1039/b810569c

This study focusses on a new concept for oligosaccharide synthesis based on 4-(pyridin-2-yl)thiazol-2-yl thioglycosides that can either act as effective glycosyl donors or can be deactivated by stable bidentate complexation with palladium(II) bromide.

Traditional linear approaches for oligosaccharide assembly are cumbersome, and consequently the availability of complex glycostructures remains insufficient to address the challenges of modern glycosciences.^{1–4} Recent improvements for oligosaccharide synthesis, *i.e.* selective activation of one leaving group over another^{5–9} or chemoselective activation of building blocks wherein reactivity is dictated by the nature of protecting groups,^{10–13} significantly shorten oligosaccharide assembly. Nevertheless, these expeditious approaches¹⁴ and even high-throughput automated^{15,16} or one-pot technologies^{17,18} are still far from being comprehensively applicable.

We have already reported a temporary deactivation concept for oligosaccharide synthesis based on the ability of *S*-thiazolanyl (STaz) glycosides to be engaged in stable non-ionizing transition metal complexes.¹⁹ As depicted in Scheme 1, this strategy allows chemoselective activation of the “free” STaz (or other) moiety on the glycosyl donor **B** over the deactivated (capped) STaz moiety on the glycosyl acceptor **A**. Upon glycosylation, the disaccharide **C** is released from the complex to provide “free” disaccharide **D**, which can be directly used as a glycosyl donor for subsequent transformations.

What remained unexplored is the ability to carry out the multistep synthesis—it would be advantageous if upon glycosylation, **C** could be converted into an acceptor **E** by removing a strategically placed substituent (P). The latter could then couple with the donor **B** to form the trisaccharide and consequently higher oligosaccharides upon reiteration of the deprotection–glycosylation sequence. Indeed, the possibility of achieving a desired oligosaccharide employing only one class of a leaving group, irrespective of the nature of the protective groups, would be very attractive. This approach should also allow for bidirectional^{20,21} (*e.g.* **D** + **A**) and convergent^{22,23} (*e.g.* **D** + **E**) couplings. Unfortunately, our attempts to apply this idea to STaz glycosides have failed due



Scheme 1 Temporary deactivation concept.

to the marginal stability of the monodentate Pd(II)STaz complex and its propensity to decomplex.

To address this challenge, we investigated a series of novel anomeric moieties that would be capable of forming more stable bidentate complexes, as depicted in Fig. 1. Herein we report our preliminary investigation of this concept, focusing primarily on 4-(pyridin-2-yl)thiazol-2-yl (PT) thioglycosides as glycosyl donors and as complexed glycosyl acceptors.

We found that bromide **1** serves as a suitable precursor for the synthesis of SPT glycosides upon reaction with readily accessible thiolate **2** (Scheme 2). The requisite SPT glycoside **3**, obtained in 99% yield, was then converted into benzylated glycosyl donor **4**. This transformation clearly demonstrated the compatibility of the SPT moiety with strongly basic reaction conditions (MeONa or NaH). The peracetate **3** was also converted into a glycosyl acceptor *via* intermediate **5**, as shown in Scheme 2.


The complexation of **5** with PdBr₂ took place quantitatively and the resulting complex was sufficiently stable to detritylation conditions to afford acceptor **6** (see Fig. 2 for crystal structure). We believe that this observation alone may serve as a viable proof of the bidentate concept, since the first generation monodentate STaz ligands were found to be unstable to detritylation. The glycosyl acceptor **6** was then glycosylated with glycosyl donor **4** in the presence of silver triflate. Upon subsequent decomplexation with NaCN, the requisite disaccharide **7** was obtained in 90% yield. It should be noted that



Fig. 1 Anomeric thiomoieties for bidentate ligation.

Department of Chemistry and Biochemistry, University of Missouri—St. Louis, One University Boulevard, St. Louis, Missouri 63121, USA. E-mail: demchenkoa@umsl.edu

† Electronic supplementary information (ESI) available: Experimental procedures for the synthesis of all new compounds and their ¹H and ¹³C NMR spectra, as well as the structure and geometrical parameters for **6**. CCDC reference number 693543. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/b810569c



Scheme 2 Synthesis/evaluation of SPT donor **4** and acceptor **6**. *Reagents and conditions:* (i) Na/MeOH; (ii) MeCN; (iii) 1. MeONa/MeOH, 2. BnBr/NaH, DMF; (iv) 1. NaOMe/MeOH, 2. TrCl, C₃H₅N, 3. BzCl; (v) 1. PdBr₂, 3 Å MS, 1,2-DCE, 2. 10% TFA/wet DCM, 0 °C; (vi) 1. AgOTf, 3 Å MS, DCM, 2. NaCN, acetone.





Fig. 2 X-Ray crystal structure of the acceptor complex **6**. Projection view of the molecule with 50% thermal ellipsoids—the disordered component and solvent have been omitted for clarity. Selected crystallographic parameters for **6**: Empirical formula C₃₈H₃₆Br₂N₂O₁₀PdS₂; formula weight 1011.03; monoclinic; space group C2, Z = 4. Unit cell dimensions: a = 26.134(2), b = 6.6651(5), c = 26.550(3) Å, β = 118.580(4)°, volume 4061.1(7) Å³; number of reflections collected 41 064; independent reflections 7012 [R(int) = 0.064]; final R indices: R1 [I > 2σ(I)] = 0.0431, wR2 (all data) = 0.0951. CCDC # 693543.

yields achieved with the STaz mediated temporary deactivation were significantly lower.¹⁹

To explore the scope of our concept, we investigated major aspects of the SPT methodology. First, we determined that the SPT–PdBr₂ complex is also stable under standard conditions for silyl group introduction/cleavage, tritylation, acylation/deacylation, and acetal formation, reductive opening and cleavage.²⁴ Second, we determined the applicability of this concept to other classes of glycosyl donors including trichloroacetimidates, thioimidates, and alkyl/aryl thioglycosides.²⁵ Third, both primary and secondary glycosyl acceptors bearing the complexed SPT moiety were obtained and tested accordingly (see ESI[†]).

The versatility of the approach developed was illustrated by the synthesis of medically relevant oligosaccharides of *Streptococcus pneumoniae* serotype 14 (SPn14), the most prevalent cause of invasive pneumococcal disease worldwide.²⁶ The bacterial isolate of SPn14 polysaccharide is poorly



Scheme 3 Synthesis of pneumococcal oligosaccharides.

immunogenic due to the abundance of similar sequences in mammalian tissues.²⁷ This complicates its use as vaccine, and as a result, scientists throughout the world have already turned their attention to the chemical synthesis of SPn14 oligosaccharides and derivatives thereof.^{28–31} The branched tetrasaccharide repeating unit of SPn14 consists of lactose linked to the C-6 of lactosamine.

To perform this synthesis, we obtained the key building blocks **8**,³² **9**, and **11** (Scheme 3). The synthesis of **9** was performed starting from known triacetyl-*N*-phthalimido bromide,³³ whereas lactose donor **11** was obtained from the corresponding ethyl thioglycoside.³¹ The STaz donor **8** was then coupled with the complexed acceptor **9** in the presence of AgOTf followed by desilylation with TBAF to allow the disaccharide acceptor **10**. The latter was then coupled with the lactose donor **11** to afford the SPn14 tetrasaccharide repeat unit **12**.

For the subsequent convergent elongation, one portion of tetrasaccharide **12** was treated with NaCN to afford glycosyl donor **13**, whereas another portion of **12** was treated with 10% TFA to afford glycosyl acceptor **14**. The coupling of **13** and **14** followed by decomplexation under the standard reaction conditions afforded octasaccharide **15**.

In conclusion, we have developed a new approach to expeditious oligosaccharide assembly. This method complements the advantageous features that made effective strategies such as orthogonal, armed–disarmed, bidirectional, and convergent, very attractive. In addition, as illustrated by the synthesis of oligosaccharide **15**, the SPT-mediated approach allows for the flexible operation (and the interchange) of the different strategies upon demand. Thus, selective activation is executed for the synthesis of **10** and **12**, whereas fundamentals of chemoselective, convergent, and bi-directional strategies are executed during the transformation of **12** into **15**. It is to be expected that the efficient synthesis of pneumococcal oligosaccharide **15** reported herein will significantly contribute to

the international scientific effort dealing with the synthesis of fully synthetic vaccines.

The authors thank NIGMS (GM077170) for financial support of this work and NSF for grants to purchase equipment (CHE-9974801, CHE-9708640, CHE-9309690, CHE-0420497). Dr R. E. K. Winter and Mr J. Kramer (UM—St. Louis) are thanked for HRMS determinations.

Notes and references

- 1 P. H. Seeberger and D. B. Werz, *Nature*, 2007, **446**, 1046–1051.
- 2 D. P. Galonic and D. Y. Gin, *Nature*, 2007, **446**, 1000–1007.
- 3 J. A. Prescher and C. R. Bertozzi, *Nat. Chem. Biol.*, 2005, **1**, 13–21.
- 4 D. H. Dube and C. R. Bertozzi, *Nat. Rev. Mol. Cell Biol.*, 2005, **4**, 477–488.
- 5 K. C. Nicolaou, R. E. Dolle, D. P. Papahatjis and J. L. Randall, *J. Am. Chem. Soc.*, 1984, **106**, 4189–4192.
- 6 R. Roy, F. O. Andersson and M. Letellier, *Tetrahedron Lett.*, 1992, **33**, 6053–6056.
- 7 O. Kanie, Y. Ito and T. Ogawa, *J. Am. Chem. Soc.*, 1994, **116**, 12073–12074.
- 8 P. P. Deshpande, H. M. Kim, A. Zatorski, T. K. Park, G. Ragupathi, P. O. Livingston, D. Live and S. J. Danishefsky, *J. Am. Chem. Soc.*, 1998, **120**, 1600–1614.
- 9 A. V. Demchenko, P. Pornsuriyasak, C. De Meo and N. N. Malysheva, *Angew. Chem., Int. Ed.*, 2004, **43**, 3069–3072.
- 10 D. R. Mootoo, P. Konradsson, U. Udodong and B. Fraser-Reid, *J. Am. Chem. Soc.*, 1988, **110**, 5583–5584.
- 11 N. L. Douglas, S. V. Ley, U. Lucking and S. L. Warriner, *J. Chem. Soc., Perkin Trans. 1*, 1998, 51–65.
- 12 Z. Zhang, I. R. Ollmann, X. S. Ye, R. Wischnat, T. Baasov and C. H. Wong, *J. Am. Chem. Soc.*, 1999, **121**, 734–753.
- 13 J. T. Smoot, P. Pornsuriyasak and A. V. Demchenko, *Angew. Chem., Int. Ed.*, 2005, **44**, 7123–7126.
- 14 A. V. Demchenko, *Lett. Org. Chem.*, 2005, **2**, 580–589.
- 15 P. H. Seeberger and D. B. Werz, *Nat. Rev. Mol. Cell Biol.*, 2005, **4**, 751–763.
- 16 P. H. Seeberger, *Chem. Soc. Rev.*, 2008, **37**, 19–28.
- 17 Y. Wang, X. S. Ye and L. H. Zhang, *Org. Biomol. Chem.*, 2007, **5**, 2189–2200.
- 18 C. C. Wang, J. C. Lee, S. Y. Luo, S. S. Kulkarni, Y. W. Huang, C. C. Lee, K. L. Chang and S. C. Hung, *Nature*, 2007, **446**, 896–899.
- 19 P. Pornsuriyasak, U. B. Gangadharmath, N. P. Rath and A. V. Demchenko, *Org. Lett.*, 2004, **6**, 4515–4518.
- 20 T. Zhu and G. J. Boons, *Angew. Chem., Int. Ed.*, 1998, **37**, 1898–1900.
- 21 T. Zhu and G. J. Boons, *Angew. Chem., Int. Ed.*, 1999, **38**, 3495–3497.
- 22 H. Paulsen, *Angew. Chem., Int. Ed. Engl.*, 1982, **21**, 155–173.
- 23 T. Ogawa, H. Yamamoto, T. Nukada, T. Kitajima and M. Sugimoto, *Pure Appl. Chem.*, 1984, **56**, 779–795.
- 24 P. G. M. Wuts and T. W. Greene, *Greene's Protective Groups in Organic Synthesis*, Wiley-Interscience, Hoboken, New Jersey, 4th edn, 2007.
- 25 *Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic Relevance*, ed. A. V. Demchenko, Wiley-VCH, Weinheim, 2008.
- 26 F. E. Babl, S. I. Pelton, S. Theodore and J. O. Klein, *Clin. Infect. Dis.*, 2001, **32**, 1155–1161.
- 27 R. Schneerson, L. Levi, J. B. Robbins, D. M. Bryla, G. Schiffman and T. Lagergard, *Infect. Immun.*, 1992, **60**, 3528–3532.
- 28 N. K. Kochetkov, N. E. Nifant'ev and L. V. Backinowsky, *Tetrahedron*, 1987, **43**, 3109–3121.
- 29 D. Michalik, J. F. G. Vliegthart and J. P. Kamerling, *J. Chem. Soc., Perkin Trans. 1*, 2002, **17**, 1973–1981.
- 30 J. A. F. Joosten, J. P. Kamerling and J. F. G. Vliegthart, *Carbohydr. Res.*, 2003, **338**, 2611–2627.
- 31 A. Sundgren, M. Lahmann and S. Oscarson, *J. Carbohydr. Chem.*, 2005, **24**, 379–391.
- 32 P. Pornsuriyasak and A. V. Demchenko, *Chem. Eur. J.*, 2006, **12**, 6630–6646.
- 33 N. K. Kochetkov, N. E. Byramova, Y. E. Tsvetkov and L. V. Backinowsky, *Tetrahedron*, 1985, **41**, 3363–3375.